Granules India Limited · NSE:GRANULES
Granules India — Q1 FY2026 Earnings Presentation
24 slides from Granules India's earnings presentation, Aug 12, 2025
Slide 1: Presentation to Analysts/Investors cover letter
G GRANULES Date: August 12, 2025 To, National Stock Exchange of India Limited BSE Limited Symbol: NSE: GRANULES: BSE: 532482 Dear Sir, Sub: Presentation to the Analysts/Investors We refer to the unaudited financial results for the first quarter of the FY 2025-2026, submitted to you today i.e., on Au
Slide 2: Granules India Limited Earnings Presentation Q1FY26
Granules India Limited Earnings Presentation Q1FY26 12th August 2025 Embracing Change. Shaping Tomorrow.
Slide 3: Safe Harbour Statement
Safe Harbour Statement The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendatio
Slide 4: Q1FY26: Table of Contents
Q1FY26: Table of Contents 1 Q1 Quarterly Performance 5 Portfolio Expansion 2 Historical Performance 6 Business Strategy 3 R&D Capability 7 Granules sustainability 4 Granules at Glance 8 CSR Initiatives Earnings Presentation – Q1FY26
Slide 5: Quarterly Performance
Quarterly Performance Q1 FY 26 Earnings Presentation – Q1FY26
Slide 6: Q1FY26: Executive Summary
Q1FY26: Executive Summary ▪ Sales: YoY Growth in North America and sequential in Europe. Lower sales in ROW primarily Financial because of PFI supply backlog from Gagillapur. ▪ Senn Chemicals AG : Revenue of ₹291 Mn. Overview ▪ EBITDA: EBITDA% is Impacted by higher manpower costs with consolidation
Slide 7: Q1FY26: Financial Overview
Q1FY26: Financial Overview (In ₹ Mn) Particular Q1 FY26 Q4 FY25 Q-o-Q Q1 FY25 Y-o-Y Revenue 12,101 11,974 1% 11,799 3% Gross Margin 7,850 7,591 3% 6,954 13% % of Gross Margin 64.9% 63.4% 148 bps 58.9% 593 bps Manpower Cost 2,028 1,691 20% 1,636 24% R&D 678 665 2% 620 9% Other Expenses 2,678 2,711 -1
Slide 8: Q1FY26: Key Financials
Q1FY26: Key Financials (In ₹ Mn) Revenue Gross Margin 7,850 Revenue 12,101 7,591 11,974 11,799 North America Growth of YoY and Europe Growth of QoQ. 6,954 Lower sales in ROW primarily because of PFI supply backlog from Gagillapur to LATAM Market Revenue of ₹291 Mn from Senn Chemicals AG 58.9 63.4 64
Slide 9: Q1FY26: Revenue split by Segments and Market
Q1FY26 : Revenue spilt by Segments and Market (In ₹ Mn) Division wise share Region wise share Q1 FY26 Q1 FY25 Q4 FY25 9% 14% 13% 2% 14% 8% 10% 8% 10% 13% 16% 12% ROW 14% Europe 77% 74% 79% North America 74% 76% 77% Q1 FY26 Q1 FY25 Q4 FY25 FD API PFI Peptides/CDMO FD API PFI FD API PFI Q1 FY26 Q1 FY2
Slide 10: Q1FY26: Cashflow and Ratios
Q1FY26: Cashflow and Ratios (In ₹ Mn) ROCE % Fixed Asset Turn Net Debt and Net Debt/ EBITDA 1.74 9,480 19.6% 1.54 1.46 7,941 16.6% 16.0% 7,061 0.77 0.75 0.96 Q1 FY25 Q4 FY25 Q1 FY26 Q1 FY25 Q4 FY25 Q1 FY26 Q1 FY25 Q4 FY25 Q1 FY26 CCC Cash Flow from CAPEX Operations 3,183 202 205 2,806 1,598 183 1,44
Slide 11: Historical Performance
Historical Performance Earnings Presentation – Q1FY26
Slide 12: Sales and Profitability: Last 6 quarters historical performance
Sales and Profitability: Last 6 quarters historical performance (In ₹ Mn) Revenue Gross Margin and % 12,101 11,758 11,799 9,667 11,375 11,974 2% 7,591 7,850 7,062 6,954 7,020 65% 5,994 63% 73% 76% 77% 76% 77% 74% 62% 62% 60% 13% 8% 8% 10% 59% 12% 10% 14% 16% 15% 12% 12% 14% Q4FY24 Q1FY25 Q2FY25 Q3FY
Slide 13: Cashflow and Ratios: Last 6 quarters historical performance
Cashflow and Ratios: Last 6 quarters historical performance (In ₹ Mn) ROCE% Asset turns Net debt and Net debt/EBITDA 9,480 19.6% 1.77 8,421 8,289 1.74 7,941 7,973 16.5% 16.9% 16.6% 7,061 16.4% 16.0% 0.96 1.56 1.56 0.86 0.90 1.54 0.98 0.77 0.75 1.46 Q4FY24 Q1FY25 Q2FY25 Q3FY25 Q4FY25 Q1FY26 Q4FY24 Q1
Slide 14: R&D Capability
R&D Capability Earnings Presentation – Q1FY26
Slide 15: R&D Product pipeline and capability building
R&D Product pipeline and capability building (In ₹ Mn) Integrated Product ✓ Total of ~412 scientist across API, FD R&D and Peptides CDMO Development Peptides Genome Valley – MN Park Senn Chemical AG ✓ Received 91 approvals till Q1FY26 R&D facility for Integrated Product Development R&D facility for
Slide 16: Granules at a glance
Granules at a glance Earnings Presentation – Q1FY26
Slide 17: Granules Purpose, Vision & Values
Granules Purpose, Vision & Values Earnings Presentation – Q1FY26
Slide 18: An Illustrious Journey Spanning Four Decades
An Illustrious Journey Spanning Four Decades Building A World Class, Vertically Integrated Pharmaceutical Manufacturing Platform From being a paracetamol API manufacturing facility to a multi-faceted global pharmaceutical company, we have consistently achieved manufacturing success, set new standard
Slide 19: Manufacturing Network & Capacity
Manufacturing Network & Capacity Bonthapally Jeedimetla Bonthapally II Vizag (Unit 4) Vizag (Unit 5) API: 4,800 TPA API (Intermediate): API: 15 KL PA API: 34,560 TPA API: 380 KL PA PFI: 1,440 TPA 61.5 KL PA FD: 1.1 Bn Gagillapur Virginia, USA GPAK, USA Genome Valley Senn Chemicals AG, Switzerland FD
Slide 20: Portfolio Expansion: On Strength Of Focused R&D Investments
Portfolio Expansion: On Strength Of Focused R&D Investments & Leveraging Our Core Capabilities Future Portfolio Current Portfolio Innovation/ Tech based products (Enzyme/ Cont. Peptides/ manufacturing) CDMO Our Legacy and our core portfolio Core Products New Core Products C II Products C II New Cont
Slide 21: Business Strategy: Building & Sustaining Key Product Leadership
Business Strategy: Building & Sustaining Key Product Leadership Key Operations and R&D Initiatives to Strengthen and Sustain Our Cost and Market Leadership Backward Integration Process Improvement Formulation Technologies Bio Catalysis + Cont. Mfg. Minimizing Carbon Footprint Earnings Presentation –
Slide 22: Sustainability at Granules: Pioneering Innovation for Decarbonization
Sustainability at Granules : Pioneering Innovation for Complete Supply Chain Decarbonization of Pharmaceuticals 23 % Scope1 and Scope2 Near-term, Long-term, and Net Zero targets (2050 or sooner), aligned to 1.5°C pathway, have been validated and approved by SBTi Intensity* *Over base year B 32 % A M
Slide 23: Our CSR Journey: Empowering Communities, Enriching Lives
Our CSR Journey : Empowering Communities, Enriching Lives OUR GOAL OUR PROGRESS Touch 1 Million 1,00,000 + Lives by 2030 Lives Positively Impacted FOCUS AREAS Skill Development 1500 + trained through Pharma Pathashala since inception in 2017 with 250+ in current year Health 10000 + Benefitted from h
Slide 24: Corporate address and investor relations contacts
For investor relation – Granules IR desk Email: investorrelations@granulesindia.com www.granulesindia.com Ms. Payal Dave payal.dave@linkintime.co.in Mr. Irfan Raeen +91 97737 78669 532482 Irfan.raeen@linkintime.co.in GRANULES www.orientcap.com GRAN:IN GRAN:NS Corporate address: 15th Floor, Granules